Showing results (151-160 of 202) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myelomaMaurizio Zangari, Elias Anaissie, Alison Stopeck, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Pageof 21